Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuronIMRN -7.91%68 3-Year EPS without NRI Growth Rate is 6.70% as of Jun. 2026, which is 9% below its 10-year median of 7.35. GuruFocus rates IMRN with a GF Score™ of 68/100 and a GF Value™ of $2.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,160 Biotechnology companies, Immuron ranks worse than 61.81% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 6.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 8.30% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 12.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Immuron was 34.30% per year. The lowest was -19.70% per year. And the median was 7.35% per year.
Immuron (NAS:IMRN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Immuron 3-Year EPS without NRI Growth Rate Related Terms
IMRN vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Immuron's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Immuron's 3-Year EPS without NRI Growth Rate falls into.
Immuron 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 6.70% mean?
Immuron (IMRN) has a 3-Year EPS without NRI Growth Rate of 6.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Immuron and its competitors. This is near median its historical median of 7.35. According to the industry distribution chart, Immuron ranks #717 out of 1160 companies in the Biotechnology industry, placing it in the top 61.8%.
Is Immuron's 3-Year EPS without NRI Growth Rate too high?
Immuron's current 3-Year EPS without NRI Growth Rate of 6.70% is near median its 10-year median of 7.35. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Immuron's value of 6.70% is 58% below this industry median. Based on the distribution chart, Immuron ranks #717 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immuron has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Immuron's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #717 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Immuron in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Immuron's value of 6.70% is 58% below this benchmark. While the company's 10-year median is 7.35 vs. the industry median of 15.95, Immuron has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuron's current 3-Year EPS without NRI Growth Rate of 6.70% is 58% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Immuron and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current 3-Year EPS without NRI Growth Rate is 6.70%, which is near median its own 10-year median of 7.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (IMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.28, compared to a current price of $1.65 — trading 27.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 6.70%, which is near median its 10-year median of 7.35 and 58% below the Biotechnology industry median of 15.95. Immuron's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Immuron (IMRN), the current 3-Year EPS without NRI Growth Rate is 6.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuron (IMRN) Overvalued in 2026?
Based on GuruFocus' analysis, Immuron stock appears to be undervalued.
The current stock price of $1.65 is trading 27.6% below its estimated GF Value™ of $2.28.
GuruFocus considers Immuron to be Modestly Undervalued.
Key valuation signals for IMRN:
3-Year EPS without NRI Growth Rate: 6.70% (near median its 10-year median of 7.35)
GF Value™: $2.28 vs. price of $1.65 (27.6% below fair value)
Industry Position: 58% below the Biotechnology median (#717 of 1160)
No single metric tells the full story. See the IMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
68GF Score
Get the complete analysis for IMRN
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMRN has been successfully added to your 
